EUCTR2020-005410-18-PL进行中（未招募）1 期
Multicentre, randomized, double-blind, placebo-controlled, non-commercial clinical trial to evaluate the efficacy and safety of specific anti-SARS-CoV-2 immunoglobulin in the treatment of COVID-19
Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie Samodzielny Publiczny Zaklad Opieki Zdrowotnej0 个研究点目标入组 480 人开始时间: 2020年11月16日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 480
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age over 18 years
- •2. Sign informed consent in order to participate in the study
- •3. SARS-CoV-2 infection (positive RT-PCR test for SARS-CoV-2)
- •4. Indication for hospitalization due to the course of COVID-19
- •5. The patient's clinical condition is assessed at 3-5 on the ORDINAL scale:
- •3 - Hospitalization without oxygen therapy
- •4 - Hospitalization with low flow oxygen support on a nasal mask or mustache
- •5 - hospitalization with high flow oxygen therapy> 15l / min without mechanical ventilation
- •6. There are no contraindications to the use of standard symptomatic treatment in accordance with the guidelines of PTEiLChZ.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 336
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 144
排除标准
- •The patient's inability to comply with the protocol in opinion of the Investigator
- •1. Intake of any experimental anti-COVID-19 study drugs
- •2. Intake of any plasma therapy, in particular plasma therapy with COVID-19 convalescents
- •3. Infection with human immunodeficiency virus (HIV)
- •4. Pregnancy or breastfeeding
- •5.All conditions that the doctor qualifying for the study considers harmful to the patient participating in this study, including any clinically significant deviations from normal clinical laboratory values ??or concurrent medical events or situations that prevent the proper performance of the study (e.g. insufficient knowledge of the Polish language by the patient in the opinion of the researcher)
- •6. Participation in another interventional clinical trial in the last 30 days.
研究者
相似试验
进行中（未招募）
1 期
Study on the treatment of the mild congnitive impairment due to Alzheimer's disease with Zinc SulphateEUCTR2019-000604-15-ITIVERSITÀ DEGLI STUDI G. D'ANNUNZIO CHIETI-PESCARA215
招募中
1 期
Study to evaluate the efficacy and safety of low-dose aspirin as an add-on to standard therapy in patients with bipolar disorder (ASPIRIN BD)Bipolar Affective DisorderMedDRA version: 21.1Level: LLTClassification code: 10004908Term: Bipolar affective disorder Class: 10037175CTIS2024-516584-86-00Instytut Psychiatrii I Neurologii100
进行中（未招募）
不适用
Multicentre, randomized, double-blind, placebo-controlled clinical trial to evaluate the short-term efficacy and safety of two different treatment regimens of Betamethasone valerate 2.25 mg medicated plaster in patients with chronic tendinopathies of the upper and lower limbsEUCTR2012-005030-11-ITIBSA INSTITUT BIOCHIMIQUE SA
进行中（未招募）
1 期
Multicentre, double-blind, randomized, placebo-controlled, parallel-group, clinical trial to evaluates the clinical efficacy and safety of immunotherapy with purified major allergen Alt a 1 in patients with allergic rhinoconjunctivitis with or without mild to moderate asthma, sensitized the fungus Alternaria alternataEUCTR2010-024440-15-ESDIATER Laboratorio de Diagnostico y Aplicaciones Terapéuticas S.A.
进行中（未招募）
不适用
Multicentre, randomised, double-blind, placebo-controlled clinical study to assess the efficacy and safety of UroVaxom in chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS) - Uro-Vaxom in patients with chronic prostatitis and chronic pelvic pain syndromeChronic prostatitis and chronic pelvic pain syndromeMedDRA version: 9.1Level: LLTClassification code 10009109Term: Chronic prostatitisMedDRA version: 9.1Level: LLTClassification code 10064189Term: Chronic pelvic pain syndromeEUCTR2007-004609-85-PTOM PHARMA200